These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
54 related articles for article (PubMed ID: 13476887)
1. As a pharmaceutical manufacturer sees it. BECKWITH ER Med Ann Dist Columbia; 1957 Nov; 26(11):611-5 passim. PubMed ID: 13476887 [No Abstract] [Full Text] [Related]
2. The outlook for peptide drugs and the intricate relationship between the Active Pharmaceutical Ingredients manufacturer and their sponsors. de Chastonay J J Pept Sci; 2005 Nov; 11(11):754-5. PubMed ID: 16215959 [TBL] [Abstract][Full Text] [Related]
3. How a pharmaceutical manufacturer tests products for sterility. Slade JW Contam Control; 1966 Apr; 5(4):11 passim. PubMed ID: 4222253 [No Abstract] [Full Text] [Related]
4. The physician looks at the pharmaceutical manufacturer and vice versa. BECKWITH ER Ariz Med; 1957 Dec; 14(12):758-63. PubMed ID: 13488747 [No Abstract] [Full Text] [Related]
5. The ethical pharmaceutical manufacturer and the hospital pharmacy. MEES JL Hosp Manage; 1958 Jul; 86(1):86 passim. PubMed ID: 13548941 [No Abstract] [Full Text] [Related]
6. Developing a tool for the preparation of GMP audit of pharmaceutical contract manufacturer. Linna A; Korhonen M; Mannermaa JP; Airaksinen M; Juppo AM Eur J Pharm Biopharm; 2008 Jun; 69(2):786-92. PubMed ID: 18191391 [TBL] [Abstract][Full Text] [Related]
7. The hidden costs of free lunches: fraud and abuse in physician-pharmaceutical arrangements. Gosfield AG J Med Pract Manage; 2005; 20(5):253-8. PubMed ID: 15921138 [TBL] [Abstract][Full Text] [Related]
8. Patient awareness and concern regarding pharmaceutical manufacturer interactions with doctors. Edwards D; Ballantyne A Intern Med J; 2009 Mar; 39(3):191-6. PubMed ID: 19383067 [TBL] [Abstract][Full Text] [Related]
9. [Is the pharmaceutical industry really as bad as its reputation?]. Prat EH Wien Med Wochenschr; 2005 Nov; 155(21-22):502-12. PubMed ID: 16425111 [TBL] [Abstract][Full Text] [Related]
10. The availability of references and the sponsorship of original research cited in pharmaceutical advertisements. Cooper RJ; Schriger DL CMAJ; 2005 Feb; 172(4):487-91. PubMed ID: 15710940 [TBL] [Abstract][Full Text] [Related]
11. The first pharmacoepidemiologic investigations: national drug safety policy in the United States, 1901-1902. Lilienfeld DE Perspect Biol Med; 2008; 51(2):188-98. PubMed ID: 18453724 [TBL] [Abstract][Full Text] [Related]
12. Allied against reform: pharmaceutical industry-academic physician relations in the United States, 1945-1970. Tobbell DA Bull Hist Med; 2008; 82(4):878-912. PubMed ID: 19075387 [TBL] [Abstract][Full Text] [Related]
13. Psychiatric training program engagement with the pharmaceutical industry: an educational issue, not strictly an ethical one. Mohl PC Acad Psychiatry; 2005; 29(2):215-21. PubMed ID: 15937270 [TBL] [Abstract][Full Text] [Related]
14. Attitudes of preclinical and clinical medical students toward interactions with the pharmaceutical industry. Hyman PL; Hochman ME; Shaw JG; Steinman MA Acad Med; 2007 Jan; 82(1):94-9. PubMed ID: 17198299 [TBL] [Abstract][Full Text] [Related]
15. Pharma on the hot seat. Huberfeld N J Health Law; 2007; 40(2):241-65. PubMed ID: 17849829 [TBL] [Abstract][Full Text] [Related]
16. Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations. Kerridge I; Maguire J; Newby D; McNeill PM; Henry D; Hill S; Day R; Macdonald G; Stokes B; Henderson K Intern Med J; 2005 Apr; 35(4):206-10. PubMed ID: 15836497 [TBL] [Abstract][Full Text] [Related]
17. Relationship between drug company funding and outcomes of clinical psychiatric research. Kelly RE; Cohen LJ; Semple RJ; Bialer P; Lau A; Bodenheimer A; Neustadter E; Barenboim A; Galynker II Psychol Med; 2006 Nov; 36(11):1647-56. PubMed ID: 16893480 [TBL] [Abstract][Full Text] [Related]
18. "But doctors do it...": nurses' views of gifts and information from the pharmaceutical industry. Jutel A; Menkes DB Ann Pharmacother; 2009 Jun; 43(6):1057-63. PubMed ID: 19470854 [TBL] [Abstract][Full Text] [Related]
19. Medicaid program; time limitation on recordkeeping requirements under the drug rebate program. Final rule. Centers for Medicare & Medicaid Services (CMS), HHS Fed Regist; 2004 Nov; 69(227):68815-8. PubMed ID: 15565749 [TBL] [Abstract][Full Text] [Related]
20. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression. Zaric GS Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]